1-2 of 2
Peter Sportelli
Close
Sort by
Journal Articles

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Brian T. Hill, Shuo Ma, Clive S. Zent, Andrea M. Baran, Danielle S. Wallace, Anjali Advani, Allison Winter, Jane Winter, Leo Gordan, Reem Karmali, Jane L. Liesveld, Deborah A. Mulford, Chris Rowland, Andrew Bui, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jonathan W. Friedberg, Paul M. Barr
Journal: Blood Advances
Blood Adv (2024) 8 (2): 378–387.
https://doi.org/10.1182/bloodadvances.2023010693
Published: 2024
Journal Articles

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Clinical Trials & Observations
Matthew S. Davids, Owen A. O’Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enrico Derenzini, Danielle M. Brander, James A. Reeves, Wanda Knopińska-Posłuszny, John N. Allan, Tycel Phillips, Paolo F. Caimi, Ewa Lech-Maranda, John M. Burke, Richy Agajanian, Ruth Pettengell, Lori A. Leslie, Chan Y. Cheah, Gustavo Fonseca, James Essell, Julio C. Chavez, John M. Pagel, Jeff P. Sharman, Yanzhi Hsu, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Ian W. Flinn
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5332–5343.
https://doi.org/10.1182/bloodadvances.2021005132
Published: 2021
Includes: Supplemental data